Leemans R, Manson W, Snijder J A, Smit J W, Klasen H J, The T H, Timens W
Department of Surgery, University of Groningen, The Netherlands.
Ann Surg. 1999 Feb;229(2):279-85. doi: 10.1097/00000658-199902000-00017.
To evaluate features of general immune function, in particular the restoration of the humoral immune response to pneumococcal capsular polysaccharides, in humans undergoing a spleen autotransplantation after splenectomy because of trauma.
After splenectomy, patients have an increased risk of overwhelming infection or sepsis involving encapsulated bacteria such as pneumococci. The value of human spleen autotransplantation after splenectomy because of trauma has long been questioned. Mononuclear phagocyte system function appeared to be similar to that in splenectomized persons. The presence of specific antipneumococcal antibodies would allow other parts of the mononuclear phagocyte system, such as those in the liver, to phagocytose opsonized bacteria.
Ten consecutive patients undergoing splenectomy followed by autotransplantation were compared with the next 14 consecutive patients undergoing splenectomy alone. After a minimum of 6 months, the patients were vaccinated with 23-valent pneumococcal vaccine. Blood samples were taken at the time of vaccination and after 3 and 6 weeks for antipneumococcal capsular polysaccharides IgM and IgG enzyme-linked immunosorbent assay against types 3, 4, 6, 9, 14, and 23. Splenic regrowth was evaluated by scintigraphy.
Surprisingly, several of the nonautotransplanted patients showed scintigraphic activity, indicating the presence of either accessory spleens or traumatic seeding (splenosis). Significant antibody titer increases (more than twofold) were found for both IgM and IgG in the autotransplanted patients. Splenectomized-only patients showed no significant increase in Ig levels in patients without splenic regrowth and partial improvement in patients with splenosis/accessory spleens.
Considering this significant antipneumococcal antibody increase, spleen autotransplants can be expected to permit an adequate humoral response to pneumococcal infections and presumably also to other TI-2 antigens, and to protect against overwhelming postsplenectomy infection or sepsis.
评估因创伤行脾切除术后接受自体脾移植的患者的一般免疫功能特征,尤其是对肺炎球菌荚膜多糖的体液免疫反应的恢复情况。
脾切除术后,患者发生暴发性感染或由肺炎球菌等包膜细菌引起的败血症的风险增加。因创伤行脾切除术后进行自体脾移植的价值长期以来一直受到质疑。单核吞噬细胞系统功能似乎与脾切除患者相似。特异性抗肺炎球菌抗体的存在将使单核吞噬细胞系统的其他部分,如肝脏中的部分,能够吞噬调理过的细菌。
将连续10例行脾切除术后自体脾移植的患者与接下来连续14例行单纯脾切除术的患者进行比较。至少6个月后,给患者接种23价肺炎球菌疫苗。在接种疫苗时以及接种后3周和6周采集血样,用于检测针对3、4、6、9、14和23型肺炎球菌荚膜多糖的IgM和IgG酶联免疫吸附试验。通过闪烁扫描评估脾再生情况。
令人惊讶的是,一些未进行自体脾移植的患者显示出闪烁扫描活性,表明存在副脾或外伤性种植(脾组织异位)。自体脾移植患者的IgM和IgG抗体滴度均显著升高(超过两倍)。单纯脾切除患者中,无脾再生的患者Ig水平无显著升高,有脾组织异位/副脾的患者Ig水平有部分改善。
考虑到这种显著的抗肺炎球菌抗体增加,预计自体脾移植能够对肺炎球菌感染以及可能对其他TI-2抗原产生足够的体液反应,并预防脾切除术后的暴发性感染或败血症。